PSAT1
Phosphoserine aminotransferase
Protein Summary
Catalyzes the reversible conversion of 3-phosphohydroxypyruvate to phosphoserine and of 3-hydroxy-2-oxo-4-phosphonooxybutanoate to phosphohydroxythreonine. This gene encodes a member of the class-V pyridoxal-phosphate-dependent aminotransferase family. The encoded protein is a phosphoserine aminotransferase and decreased expression may be associated with schizophrenia. Mutations in this gene are also associated with phosphoserine aminotransferase deficiency. Alternative splicing results in multiple transcript variants. Pseudogenes of this gene have been defined on chromosomes 1, 3, and 8. [provided by RefSeq, Jul 2013]
- ENST00000347159
- ENSP00000317606
- ENSG00000135069
- ENST00000376588
- ENSP00000365773
- PSA
- PSA
- EPIP
- NLS2
- PSAT
- PSATD
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 0.99 | ||
gene perturbation | 0.97 | ||
small molecule perturbation | 0.96 | ||
transcription factor perturbation | 0.96 | ||
disease perturbation | 0.95 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 400.23 (req: < 5)
Gene RIFs: 35 (req: <= 3)
Antibodies: 212 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 400.23 (req: >= 5)
Gene RIFs: 35 (req: > 3)
Antibodies: 212 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0